List of Safyral drug patents
Safyral is owned by Bayer Hlthcare.
Safyral contains Drospirenone; Ethinyl Estradiol; Levomefolate Calcium.
Safyral has a total of 2 drug patents out of which 1 drug patent has expired.
Expired drug patents of Safyral are:
- US7163931
Safyral was authorised for market use on 16 December, 2010.
Safyral is available in tablet;oral dosage forms.
Safyral can be used as prevention of pregnancy.
The generics of Safyral are possible to be released after 08 February, 2030.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(1 year, 24 days ago) | |
| US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(6 years from now) | |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 16 December, 2010
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
SAFYRAL family patents
8
United States
3
Australia
3
Korea, Republic of
3
European Union
2
Israel
2
Denmark
2
Slovenia
2
Hungary
2
Croatia
2
Spain
2
Czech Republic
2
China
2
Japan
2
EA
2
Canada
2
ME
1
South Africa
1
IB
1
Slovakia
1
Austria
1
Mexico
1
Hong Kong
1
Lithuania
1
Uruguay
1
Norway
1
Germany
1
Argentina
1
Brazil
1
Portugal
1
Cyprus
1
Yugoslavia
1
Peru
1
Poland
1
RS
1
Taiwan, Province of China
1
Ukraine
1
Bulgaria
1
Estonia
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic